

## PHENYTOIN – INTRAVENOUS (LOADING DOSAGE IN STATUS EPILEPTICUS) Supporting information

This guideline has been prepared with reference to the following:

BNF. Phenytoin. 2022. British National Formulary

<http://bnf.nice.org.uk/drug/phenytoin.html>

Karnes, J et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109:302-9

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831382/>

Chamberlain JM, Kapur J, Shinnar S et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet 2020. 395:1217-24

Shorvon S & Sen A. What is status epilepticus and what do we know about its epidemiology? Seizure 2020;75: 131-6

Lyttle MD, Rainford NEA, Gamble C et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019. 393: 2125-34

Patsalos PN, Spencer EP & Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit. 2018;40:526-48

Schachter SC. Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects. UpToDate. 2016

Conway JM, Henry TR. Antiepilepsy Drugs: Mechanisms of Actions and Pharmacokinetics. Epilepsy Board Rev Man. 2012;1:1-1.

Shorvon S, Ferlisi M. The Treatment of Super-refractory Status Epilepticus. Brain. 2011;134:2802-18.

European Federation of Neurological Societies. EFNS guideline on the management of status epilepticus in adults. 2009. EFNS

<https://dx.doi.org/10.1111/j.1468-1331.2009.02917.x>

Walker SP, Permezel M, Berkovic SF. The management of epilepsy in pregnancy. BJOG 2009;116: 758-67

**Last amended June 2022**  
**Last reviewed November 2023**